BR112023015410A2 - Composições e métodos que compreendem extrato de cânhamo para tratamento de animais em necessidade - Google Patents

Composições e métodos que compreendem extrato de cânhamo para tratamento de animais em necessidade

Info

Publication number
BR112023015410A2
BR112023015410A2 BR112023015410A BR112023015410A BR112023015410A2 BR 112023015410 A2 BR112023015410 A2 BR 112023015410A2 BR 112023015410 A BR112023015410 A BR 112023015410A BR 112023015410 A BR112023015410 A BR 112023015410A BR 112023015410 A2 BR112023015410 A2 BR 112023015410A2
Authority
BR
Brazil
Prior art keywords
methods
need
animals
compositions
treatment
Prior art date
Application number
BR112023015410A
Other languages
English (en)
Inventor
Joseph Wakshlag
Original Assignee
Portland Tech Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portland Tech Holdings Llc filed Critical Portland Tech Holdings Llc
Publication of BR112023015410A2 publication Critical patent/BR112023015410A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

composições e métodos que compreendem extrato de cânhamo para tratamento de animais em necessidade. esta divulgação refere-se a composições e métodos de ocorrência não natural ou manipulados que compreendem um ou mais extratos de cânhamo para o tratamento de doenças, distúrbios, síndromes e/ou condições em animais em necessidade.
BR112023015410A 2021-02-11 2022-02-11 Composições e métodos que compreendem extrato de cânhamo para tratamento de animais em necessidade BR112023015410A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163148467P 2021-02-11 2021-02-11
US202163197179P 2021-06-04 2021-06-04
PCT/US2022/070630 WO2022174255A1 (en) 2021-02-11 2022-02-11 Compositions and methods comprising hemp extract for the treatment of animals in need

Publications (1)

Publication Number Publication Date
BR112023015410A2 true BR112023015410A2 (pt) 2023-10-31

Family

ID=82837956

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023015410A BR112023015410A2 (pt) 2021-02-11 2022-02-11 Composições e métodos que compreendem extrato de cânhamo para tratamento de animais em necessidade

Country Status (7)

Country Link
US (1) US20240075087A1 (pt)
EP (1) EP4291173A1 (pt)
JP (1) JP2024506660A (pt)
AU (1) AU2022220037A1 (pt)
BR (1) BR112023015410A2 (pt)
CA (1) CA3209808A1 (pt)
WO (1) WO2022174255A1 (pt)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2981099A (en) * 1998-03-09 1999-09-27 Trustees Of Tufts College Treatment of compulsive behaviours in man and animals
GB2450741A (en) * 2007-07-05 2009-01-07 Gw Pharma Ltd Cannabinoid containing plant extracts in the treatment of inflammatory bowel disease
CN111936126A (zh) * 2018-01-24 2020-11-13 博塔尼克斯制药有限公司 用于皮炎和炎症性皮肤病的大麻素给药方案
US20200009077A1 (en) * 2018-07-03 2020-01-09 TRUETIVA, Inc. Compositions for treating dermatological diseases
WO2020014200A1 (en) * 2018-07-09 2020-01-16 Volker Berl Stabilized formulations of cannabinoid compositions
US11752127B2 (en) * 2019-04-01 2023-09-12 Virbac Corporation Methods and compositions for treatment of anxiety in animals
WO2021003341A1 (en) * 2019-07-02 2021-01-07 Ellevet Sciences Hemp extract for treatment of pain, cancer and epilepsy in animals

Also Published As

Publication number Publication date
AU2022220037A1 (en) 2023-08-17
EP4291173A1 (en) 2023-12-20
US20240075087A1 (en) 2024-03-07
CA3209808A1 (en) 2022-08-18
WO2022174255A1 (en) 2022-08-18
JP2024506660A (ja) 2024-02-14

Similar Documents

Publication Publication Date Title
MX2017011037A (es) Bacteria manejada geneticamente para tratar enfermedades que se benefician de inflamacion intestinal reducida y/o barrera mucosa intestinal fortalecida.
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
BR112017007975A2 (pt) composições e métodos para o tratamento de disfunção das glândulas meibomianas
BR112018003967A2 (pt) tratamento de hipersensibilidade à picada de inseto
BR112021026854A2 (pt) Extrato de cânhamo para tratamento da dor, câncer e epilepsia em animais
MX2022012536A (es) Composiciones que comprenden polisacaridos sulfatados.
CR10552A (es) Metodos para tratar y limitar trastornos fibroticos y queloides
CY1119633T1 (el) Νεες φαρμακοτεχνικες μορφες αποτελουμενες απο φυτικα εκχυλισματα
BR112017014649A2 (pt) ?isolado intestinal humano, e, composição?
BR112014015354A8 (pt) composição de extratos enriquecidos com elagitaninos no bem-estar sexual
JOP20190241B1 (ar) مستحضرات رذاذ إبينيفرين
BR112017017599A2 (pt) métodos para modular respostas imunológicas e inflamatórias pela administração de uma biomassa algal
EA202193111A1 (ru) Композиции и способы для лечения рака
BR112022002122A2 (pt) Composição de mascaramento de sabor dispersível oralmente de hemibromidrato de vortioxetina, método para preparação da composição de mascaramento de sabor dispersível oralmente, e método para tratamento de um transtorno de depressão em um indivíduo
WO2016127059A3 (en) Light inhibitors for scleroderma and skin fibrotic disease treatment
BR112017007066A2 (pt) composições e métodos para melhorar a mobilidade ou a atividade, ou tratar a debilidade
BR112023015410A2 (pt) Composições e métodos que compreendem extrato de cânhamo para tratamento de animais em necessidade
BR112019025625A2 (pt) Tratamento de distúrbios cutâneos
MX2021003006A (es) Bacterioterapia contra proprionibacterium acnes para el tratamiento de acne.
BR112022015533A2 (pt) Composições e métodos para tratar doenças oculares
BR112018014762A2 (pt) método de tratamento da doença de alzheimer (da) precoce
BR112023024465A2 (pt) Usos de um modulador de somatostatina para o tratamento de doença
MX2023005591A (es) Metodos de tratamiento de enfermedades y trastornos.
BR112022003639A2 (pt) Agente bioestimulante para tratamento de plantas e/ou de sementes de plantas
BR112022020012A2 (pt) Composições que compreendem 15-hepe e métodos de tratamento ou prevenção de distúrbios hematológicos e/ou doenças relacionadas